Eliem Therapeutics (NASDAQ:ELYM) on Thursday said, it would acquire Tenet Medicines, as the combined company plans to focus on clinical development of lead product candidate, TNT119, in upcoming Phase...
Source LinkEliem Therapeutics (NASDAQ:ELYM) on Thursday said, it would acquire Tenet Medicines, as the combined company plans to focus on clinical development of lead product candidate, TNT119, in upcoming Phase...
Source Link
Comments